782 related articles for article (PubMed ID: 10096792)
1. Is glucagon-like peptide 1 an incretin hormone?
Nauck MA
Diabetologia; 1999 Mar; 42(3):373-9. PubMed ID: 10096792
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective.
Nauck MA
Acta Diabetol; 1998 Oct; 35(3):117-29. PubMed ID: 9840447
[TBL] [Abstract][Full Text] [Related]
3. The physiological role of GLP-1 in human: incretin, ileal brake or more?
Schirra J; Göke B
Regul Pept; 2005 Jun; 128(2):109-15. PubMed ID: 15780430
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential.
Holst JJ
Curr Med Chem; 1999 Nov; 6(11):1005-17. PubMed ID: 10519910
[TBL] [Abstract][Full Text] [Related]
5. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
6. Incretin hormones--an update.
Holst JJ; Orskov C
Scand J Clin Lab Invest Suppl; 2001; 234():75-85. PubMed ID: 11713984
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 in NIDDM.
Holst JJ
Diabet Med; 1996 Sep; 13(9 Suppl 6):S156-60. PubMed ID: 8894501
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
Gefel D; Barg Y; Zimlichman R
Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
[TBL] [Abstract][Full Text] [Related]
10. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
Meier JJ; Kemmeries G; Holst JJ; Nauck MA
Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
[TBL] [Abstract][Full Text] [Related]
11. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
Nauck MA; Holst JJ; Willms B; Schmiegel W
Exp Clin Endocrinol Diabetes; 1997; 105(4):187-95. PubMed ID: 9285204
[TBL] [Abstract][Full Text] [Related]
13. Enteroglucagon.
Holst JJ
Annu Rev Physiol; 1997; 59():257-71. PubMed ID: 9074764
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 and control of insulin secretion.
Thorens B
Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Nauck M
Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
[TBL] [Abstract][Full Text] [Related]
16. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 1(GLP-1) in biology and pathology.
Meier JJ; Nauck MA
Diabetes Metab Res Rev; 2005; 21(2):91-117. PubMed ID: 15759282
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1.
Nagell CF; Wettergren A; Pedersen JF; Mortensen D; Holst JJ
Scand J Gastroenterol; 2004 Apr; 39(4):353-8. PubMed ID: 15125467
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
Näslund E; Gutniak M; Skogar S; Rössner S; Hellström PM
Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726
[TBL] [Abstract][Full Text] [Related]
20. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
